Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QOL-ET-BC
2024-513442-10-00Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised trial of duloxetine, furosemide and amiloride in breast cancer and Musculoskeletal pain (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Change from baseline in skeletal scale (EORTC QLQ-BR42) at month 3. Planned start Feb 2025; status: withdrawn.
02
Drugs
duloxetinefurosemideamiloride
03
Conditions
breast cancerMusculoskeletal pain
Beyond the preview
Go deeper on 2024-513442-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513442-10-00.